Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Novo Nordisk priced it at a self-pay entry point of $149/month for the lowest dose, making it the most affordable GLP-1 obesity treatment to date
Regulatory authorities continue to review emerging safety data as longer-term studies become available, ensuring that prescribing guidance reflects the most current evidence base
, ,
Concerning secondary outcomes, semaglutide was associated with the lowest risk for somatic hospitalization (aHR = 0.78
Anderberg RH, Richard JE, Hansson C, et al
US$ 24.54
US$ 22.70
US$ 27.39
US$ 20.70
US$ 23.92
US$ 24.05
![Tirzepatide vs. Semaglutide: Which GLP-1 Better Preserves Muscle? [SURMOUNT-5 Data]](https://www.clinicalnutritioncenter.com/wp-content/uploads/2026/04/research-image-2026-04-10.jpg)
US$ 23.82
